V

    Viatris Inc (VTRS)

    Official site

    HEALTHCARE • DRUG MANUFACTURERS - SPECIALTY & GENERIC • NASDAQ

    $16.51
    +0.17 (+1.04%)

    Market Cap: $18.96B

    Last updated: Sep 01, 2026 at 5:00 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    75%(30/40)
    Avg Surprise
    +3.97%
    Streak
    6 Q

    Upcoming Estimates

    Period ending Sep 30, 2026
    EPS Consensus$0.65
    Range$0.61 - $0.69
    8 analysts
    EPS Revisions
    1
    0
    7d
    1
    3
    30d
    EPS Estimate Drift
    90d ago$0.65-0.5%
    60d ago$0.65+0.0%
    30d ago$0.64-0.8%
    7d ago$0.65+0.2%
    Current$0.65
    Revenue Consensus
    $3.8B
    Range$3.7B - $3.9B
    7 analysts
    Period ending Dec 31, 2026
    EPS Consensus$0.75
    Range$0.71 - $0.83
    9 analysts
    Revenue Consensus
    $3.9B
    Range$3.8B - $4.1B
    7 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$0.75---
    Sep 26EST
    		-$0.65---
    Jun 26
    Reported Aug 6
    		$0.69$0.62+11.29%Beat+11.3%
    Mar 26
    Reported May 7
    		$0.59$0.50+18.00%Beat+18.0%
    Dec 25
    Reported Feb 26
    		$0.57$0.52+9.62%Beat+5.6%
    Sep 25
    Reported Nov 6
    		$0.67$0.62+8.06%Beat-10.7%
    Jun 25
    Reported Aug 7
    		$0.62$0.56+10.71%Beat-10.1%
    Mar 25
    Reported May 8
    		$0.50$0.49+2.04%Beat-25.4%
    Dec 24
    Reported Feb 27
    		$0.54$0.57-5.59%Miss-12.9%
    Sep 24
    Reported Nov 7
    		$0.75$0.68+10.29%Beat-5.1%
    Jun 24
    Reported Aug 8
    		$0.69$0.68+1.47%Beat-8.0%
    Mar 24
    Reported May 9
    		$0.67$0.67+0.00%Beat-13.0%
    Dec 23
    Reported Feb 28
    		$0.62$0.65-4.62%Miss-7.5%
    Sep 23
    Reported Nov 7
    		$0.79$0.74+6.76%Beat-9.2%
    Jun 23
    Reported Aug 7
    		$0.75$0.71+5.63%Beat-14.8%
    Mar 23
    Reported May 8
    		$0.77$0.70+10.00%Beat-17.2%
    Dec 22
    Reported Feb 27
    		$0.67$0.72-6.94%Miss-16.3%
    Sep 22
    Reported Nov 7
    		$0.87$0.84+3.57%Beat-12.1%
    Jun 22
    Reported Aug 8
    		$0.88$0.82+7.32%Beat-10.2%
    Mar 22
    Reported May 9
    		$0.93$0.83+12.05%Beat+1.1%
    Dec 21
    Reported Feb 28
    		$0.80$0.83-3.61%Miss-25.9%
    Sep 21
    Reported Nov 8
    		$0.99$0.88+12.50%Beat-24.4%
    Jun 21
    Reported Aug 9
    		$0.98$0.88+11.36%Beat-11.7%
    Mar 21
    Reported May 10
    		$0.92$0.80+15.00%Beat+2.2%
    Dec 20
    Reported Mar 1
    		$1.08$1.24-12.90%Miss-22.9%
    Sep 20
    Reported Nov 6
    		$1.31$1.16+12.93%Beat+12.0%
    Jun 20
    Reported Aug 6
    		$1.11$0.98+13.27%Beat+7.8%
    Mar 20
    Reported May 11
    		$0.90$0.87+3.45%Beat+9.8%
    Dec 19
    Reported Feb 27
    		$1.40$1.28+9.38%Beat+7.7%
    Sep 19
    Reported Nov 5
    		$1.17$1.14+2.63%Beat-6.4%
    Jun 19
    Reported Jul 29
    		$1.03$0.95+8.42%Beat-3.7%
    Mar 19
    Reported May 7
    		$0.82$0.79+3.80%Beat-14.6%
    Dec 18
    Reported Feb 26
    		$1.30$1.36-4.41%Miss-9.1%
    Sep 18
    Reported Nov 5
    		$1.25$1.19+5.04%Beat+13.6%
    Jun 18
    Reported Aug 8
    		$1.07$1.22-12.30%Miss-2.7%
    Mar 18
    Reported May 9
    		$0.96$0.96+0.00%Beat+3.2%
    Dec 17
    Reported Feb 28
    		$1.43$1.41+1.42%Beat-8.9%
    Sep 17
    Reported Nov 6
    		$1.10$1.20-8.33%Miss-20.3%
    Jun 17
    Reported Aug 9
    		$1.10$1.16-5.17%Miss-
    Mar 17
    Reported May 10
    		$0.93$0.92+1.09%Beat-
    Dec 16
    Reported Mar 1
    		$1.57$1.42+10.56%Beat-
    Sep 16
    Reported Nov 9
    		$1.38$1.45-4.83%Miss-

    Dividends

    Dividend Metrics

    Yield2.91%
    Annual/Share$0.48
    Payout Ratio23.96%
    Frequency4
    Pay MonthsMar, Jun, Sep, Dec

    Growth

    3Y CAGR+0.00%
    View VTRS's full dividend history

    Key Metrics

    Valuation
    P/E Ratio6.55EV/EBITDA12.02x
    Price/FCF9.83xFCF Yield10.18%
    Profitability
    Profit Margin-2.79%Operating Margin12.60%
    ROE-2.75%ROIC1.75%
    Financial Health
    Debt/Equity0.87xInterest Coverage1.35x
    Current Ratio1.58xQuick Ratio0.96x
    Trading Statistics
    Beta0.89Avg Volume9.88M
    52-Week High$18.2552-Week Low$9.11

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$16.44
    SMA 20$16.42
    SMA 50$16.57
    SMA 200$14.43
    EMA 10$16.50
    EMA 20$16.52
    EMA 50$16.43
    EMA 200$14.55

    MACD

    Line: -0.03Signal: -0.07Hist: 0.04

    ADX

    ADX: 15.2+DI: 18.5-DI: 20.6

    Aroon & PSAR

    Aroon Up32.0
    Aroon Down56.0
    PSAR$16.00

    Bollinger Bands

    Upper Band$17.37
    Lower Band$15.47
    %B Position1160%(Upper)
    Band Width0.55

    RSI (14-Day)

    Neutral
    49.6

    Momentum Oscillators

    Stoch %K57.4
    Stoch %D63.6
    Williams %R-48.4
    ROC (10d)2.5%
    Momentum0.40
    CCI (20d)-21.4
    MFI (14d)47.9

    Volatility Measures

    ATR (14d)$0.48(2.9%)
    StdDev (20d)0.48
    Hist Vol33.1%(Moderate)

    Volume Flow

    VWAP$16.40
    OBV345.4M
    AD Line-8.1B
    CMF (20d)-0.590

    Volume Metrics

    Avg Vol (20d)9.9M
    Vol Ratio1.3x
    VWMA (20d)$16.38

    Pivot Points

    R3$17.52
    R2$17.26
    R1$16.80
    Pivot Point$16.55
    S1$16.09
    S2$15.83
    S3$15.37

    Advanced Oscillators

    TSI-2.59
    Ultimate Osc47.9
    KST-28.67

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$3.76B$3.52B$3.70B$3.76B$3.58B$3.25B$3.53B$3.75B$3.80B$3.66B$3.84B$3.94B
    Cost of Revenue$2.30B$2.36B$2.56B$2.39B$2.25B$2.09B$2.31B$2.29B$2.35B$2.16B$2.24B$2.25B
    Gross Profit$1.46B$1.16B$1.15B$1.37B$1.33B$1.16B$1.22B$1.46B$1.45B$1.50B$1.60B$1.69B
    Operating Expenses$1.45B$1.24B$1.34B$1.19B$1.10B$4.04B$1.39B$1.23B$1.69B$1.30B$2.05B$1.24B
    R&D$248.30M$248.60M$323.00M$250.40M$218.80M$222.00M$234.80M$198.40M$204.10M$199.70M$308.30M$211.20M
    SG&A$1.13B$928.80M$1.03B$886.60M$928.70M$948.10M$1.05B$1.00B$1.04B$1.02B$1.03B$1.05B
    Operating Income$6.30M$-79,700,000$-192,700,000$178.80M$233.00M$-2,882,200,000$-179,800,000$225.90M$-239,900,000$203.90M$-454,500,000$451.70M
    Interest Income$0$0$0$0$0$0$0$0$0$0$0$0
    Interest Expense$120.70M$120.10M$119.60M$119.60M$116.60M$115.50M$120.20M$145.60M$145.80M$138.40M$140.90M$141.50M
    Income Before Tax$-64,000,000$-247,300,000$-343,000,000$-7,900,000$-217,100,000$-3,097,000,000$-526,500,000$90.50M$-391,800,000$204.60M$-855,000,000$402.20M
    Income Tax Expense$54.80M$-423,700,000$-2,900,000$120.30M$-212,500,000$-55,000,000$-10,000,000$-4,300,000$-65,400,000$90.70M$-89,400,000$70.60M
    Net Income$-118,800,000$176.40M$-340,100,000$-128,200,000$-4,600,000$-3,042,000,000$-516,500,000$94.80M$-326,400,000$113.90M$-765,600,000$331.60M
    EBITDA$729.00M$548.90M$543.40M$800.20M$577.80M$-2,316,800,000$339.90M$905.80M$540.30M$1.03B$-69,700,000$1.22B
    EBIT$56.70M$-127,200,000$-223,400,000$111.70M$-100,500,000$-2,981,500,000$-406,300,000$236.10M$-246,000,000$343.00M$-714,100,000$543.70M
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about VTRS

    Government Contracts

    Gov Obligations (TTM)
    -$0
    Gov Obligations / Revenue
    0.0%
    Obligations YoY
    N/A
    Active Awards
    2
    New Awards (TTM)
    0
    Avg Remaining Term
    N/A

    Federal contract obligations are bookings recorded by the awarding agency, not recognized revenue. They can exceed 100% of revenue and can be negative when contracts are de-obligated. Source: USAspending.gov prime awards, data through Jul 31, 2026.

    News

    Trump Announces Drug Pricing Deals With Teva and 8 Other Companies

    President Donald Trump announced new drug pricing deals with the U.S. affiliate of Teva Pharmaceutical Industries and eight other midsize companies. This builds on previous agreements, bringing the total number of major pharmaceutical companies with pricing agreements with the Trump administration to 17. The announcement was made during an event in the Oval Office.

    Barron's•9/1/26•
    Neutral

    Viatris Inc. stock rises Tuesday, outperforms market

    Viatris Inc. (VTRS) stock increased by 1.09% on Tuesday, closing at $16.72, outperforming the broader market. The S&P 500 Index rose by 0.32% and the Dow Jones Industrial Average rose by 0.30% on the same day. This marks the third consecutive day of gains for Viatris Inc. shares.

    MarketWatch•8/25/26•
    Bullish

    Viatris Inc. stock rises Monday, outperforms market

    Viatris Inc. (VTRS) stock rose 1.35% on Monday, closing at $16.54, outperforming the mixed market. The Dow Jones Industrial Average saw a slight gain, while the S&P 500 Index experienced a decline. This marks the second consecutive day of gains for Viatris Inc. shares.

    MarketWatch•8/24/26•
    Bullish

    Viatris Inc. stock rises Friday, outperforms market

    Viatris Inc. (VTRS) stock advanced by 2.00% on Friday, closing at $16.32, outperforming the broader market. The S&P 500 Index and Dow Jones Industrial Average also saw gains. Viatris Inc. is currently 11.26% below its 52-week high of $18.39, reached on August 6th.

    MarketWatch•8/21/26•
    Bullish

    Jazz Pharmaceuticals (JAZZ) As HER2 Pipeline Progress Fuels An Undervalued Narrative

    Jazz Pharmaceuticals (JAZZ) is gaining investor attention due to its HER2 pipeline progress, particularly for gastroesophageal adenocarcinoma, and is currently deemed 11.6% undervalued with a fair value of $281.35. Despite a recent share price pullback, the company shows strong year-to-date and one-year returns, driven by R&D, commercialization efforts, and international expansion, although potential risks like generic pressure and trial underperformance exist.

    Simply Wall Street•8/21/26•
    Somewhat-Bullish

    Frequently Asked Questions About VTRS

    What is VTRS's current dividend yield?
    Viatris Inc (VTRS) has a current dividend yield of 2.91%.
    Does VTRS pay dividends?
    Yes, Viatris Inc pays dividends with a current yield of 2.91%.
    What is VTRS's P/E ratio?
    Viatris Inc has a price-to-earnings (P/E) ratio of 6.55.
    What is VTRS's market cap?
    Viatris Inc (VTRS) has a market capitalization of $18.96B with a current stock price of $16.51.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In